“Has any member of the press actually spoken with her? Does she even exist? All I’ve seen of her is a picture of a woman with sunglasses. Is she a deaf mute?”
That’s what I am wondering as well. Did the reporter at the WaPo who wrote the article actually verify the identity of the person they were interviewing? Was the interview conducted in person or over the phone?
I think that if an actual reporter dug into this woman’s crazy story they would discover that it was nothing more than a sham, probably concocted by Fusion GPS or some group like them. All they needed was someone who had been in school in DC at the same time as Judge Kavanaugh and who would agree to let their name be used in order to stop the appointment. No one ever expected him to fight back and now they’re running around like chickens with their heads cut off trying to extricate themselves from this mess without getting caught!
“Ah, what a tangled web we weave when first we practice to deceive.” Sir Walter Scott
Wouldn’t it be delicious if Balsey was a 4 chan Troll?
>>I think that if an actual reporter dug into this woman’s crazy story they would discover that it was nothing more than a sham, probably concocted by Fusion GPS or some group like them.<<
Well, I read through 120+ comments and so far no one’s brought this up, so here goes.
There’s a story out there that’s so good that it can’t really be true, but it looks like it is. Blasey-Ford worked for Corcept Therapeutics (CORT) and at least until recently was still listed as a Director of a department there. Apparently she’s a professor now, but could still retain the position at Corcept. I don’t know.
Here’s the good part: Corcept has only one revenue source presently, a drug they call Korlym. They advertise it as a treatment for the symptoms of Cushing Syndrome. Boring stuff, right?
Here’s the interesting part: Korlym is the brand name; the drug is actually mifepristone. Another brand name for mifepristone is RU 486. Ring a bell? RU 486 is the next-day abortion drug.
As we know, doctors often prescribe drugs for off-label uses. Here are Corcept’s annual sales starting in 2014: $26mm, $50mm, $81mm, and $159mm in 2017. Sales this year are on track to exceed $250 million. It’s a good bet that the growth is due to increasing usage of the next-day abortion drug known as RU 486, or Korlym if sold by Corcept Therapeutics.
A question Ms. Blasey-Ford should be asked on Thursday is “How many shares of CORT do you currently own?” The point, obviously, is that Ms. Blasey-Ford could have a financial interest in keeping Roe v Wade the law of the land.